testosterone

AbbVie wins reversal of $140 million verdict in case over AndroGel risks
AbbVie wins reversal of $140 million verdict in case over AndroGel risks
Reuters
AbbVie
Androgel
testosterone
Flag link:
After setting aside $200M, Endo settles 1,300 testosterone liability lawsuits
After setting aside $200M, Endo settles 1,300 testosterone liability lawsuits
Fierce Pharma
Endo International
testosterone
Flag link:
U.S. jury orders AbbVie to pay $3 million in AndroGel retrial
U.S. jury orders AbbVie to pay $3 million in AndroGel retrial
Reuters
AbbVie
Androgel
testosterone
Flag link:
Endo, GlaxoSmithKline close to settling testosterone liability cases
Endo, GlaxoSmithKline close to settling testosterone liability cases
Fierce Pharma
Endo Pharmaceuticals
GSK
Auxilium
testosterone
Flag link:
The FDA still hates low T drugs — experts bat back a pair of contenders
The FDA still hates low T drugs — experts bat back a pair of contenders
Endpoints
FDA
testosterone
Lipocine
Tlando
Clarus Therapeutics
Jatenzo
Flag link:
Endo unit cleared of liability in first testosterone replacement trial
Endo unit cleared of liability in first testosterone replacement trial
Reuters
Endo International
Auxilium
Testim
testosterone
Flag link:
AbbVie hit with $140M verdict in second bellwether AndroGel case
AbbVie hit with $140M verdict in second bellwether AndroGel case
Fierce Pharma
AbbVie
Androgel
heart attacks
testosterone
Flag link:
Repros to drop testosterone drug in U.S. if key study fails
Repros to drop testosterone drug in U.S. if key study fails
Yahoo/Reuters
Repros
testosterone
FDA
clinical trials
Androxal
uterine fibroids
Proellex
Flag link:
Apricus shares are routed after testosterone drug fails to deliver clinical benefits
Apricus shares are routed after testosterone drug fails to deliver clinical benefits
Fierce Biotech
Apricus Biosciences
testosterone
fispemifene
Flag link:
Repros tanks on another FDA hurdle for its 'low-T' treatment
Repros tanks on another FDA hurdle for its 'low-T' treatment
Fierce Biotech
Repros Therapeutics
testosterone
FDA
Androxal
Flag link:
AbbVie Challenges Fairness Of Upcoming Testosterone Trials
AbbVie Challenges Fairness Of Upcoming Testosterone Trials
Forbes
AbbVie
testosterone
Androgel
Flag link:
Experts urge FDA to step in to quash 'Low-T' awareness efforts
Experts urge FDA to step in to quash 'Low-T' awareness efforts
Fierce Pharma Marketing
FDA
testosterone
off-label
Flag link:
What's Next For The Thousands Of Angry Men Suing Over Testosterone?
What's Next For The Thousands Of Angry Men Suing Over Testosterone?
Forbes
testosterone
AbbVie
Endo Health Solutions
Flag link:
Repros shares rally on testicle-stimulation drug application
Repros shares rally on testicle-stimulation drug application
Marketwatch
Repros Therapeutics
testosterone
enclomiphene citrate
Androxal
Flag link:
FDA warning: men's testosterone drugs overused
FDA warning: men's testosterone drugs overused
Yahoo/AP
FDA
warnings
testosterone
AbbVie
Eli Lilly
Axiron
Androgel
Flag link:
Niche Low-T lifestyle clinics might give suffering Lilly, AbbVie meds a boost
Niche Low-T lifestyle clinics might give suffering Lilly, AbbVie meds a boost
Fierce Pharma Marketing
testosterone
Eli Lilly
AbbVie
Axiron
Androgel
Flag link:
Repros plummets as the FDA deals a blow to its low-T hopes
Repros plummets as the FDA deals a blow to its low-T hopes
Fierce Biotech
Repros Therapeutics
testosterone
FDA
Androxal
Flag link:
Lipocine testosterone therapy meets late-stage study goals
Lipocine testosterone therapy meets late-stage study goals
Yahoo/Reuters
Lipocine
testosterone
LPCN 1021
Flag link:
FDA advisers shoot down Clarus' pitch for a new low-T drug
FDA advisers shoot down Clarus' pitch for a new low-T drug
Fierce Biotech
FDA
Clarus Therapeutics
advisory panels
Rextoro
testosterone
Flag link:
FDA panel recommends scaling back testosterone use in men, citing little evidence of benefit
FDA panel recommends scaling back testosterone use in men, citing little evidence of benefit
Yahoo/AP
FDA
advisory panels
testosterone
AbbVie
Eli Lilly
Flag link:

Pages